the identification of new molecular subtypes whose evaluation has become routine in GBM diagnosis. Such advances hold promise for the development of new therapeutic strategies in GBM.
Standard Therapy for Glioblastoma
The current standard of care for newly diagnosed GBM patients is resection followed by postoperative radiation therapy (RT) with concurrent and adjuvant temozolomide. Surgery serves to alleviate symptoms of mass effect, reduce tumor burden, and provide adequate tissue for diagnosis and molecular profiling. Although randomized evidence for the efficacy of maximal surgical resection is limited, numerous retrospective studies and a meta-analysis of 41,117 patients have found that gross total resection improves overall and progression-free survival relative to subtotal resection. 9 Furthermore, fluorescence-guided surgery using 5-aminolevulinic acid, which allows for more complete resection, was found to improve progression-free survival in a randomized trial. 10 Based on this and other evidence, maximal safe resection is considered the current standard for GBM treatment.
Postoperative radiation was established as the cornerstone of adjuvant therapy for GBM by the Brain Tumor Study Group (BTSG) 69-01 trial, which showed that whole brain radiation improved overall survival (median 35 versus 14 weeks).
11 Radiation dose was subsequently examined in a pooled analysis of BTSG trials showing longer survival for 60 Gy compared with 45 Gy, 12 which was confirmed in a subsequent randomized trial by the Medical Research Council, 13 making 60 Gy the standard of care. Further dose escalation to 70 Gy failed to improve survival, 14 as did stereotactic radiosurgery boost. 15 Modern guidelines typically call for the treatment of the postsurgical resection cavity, any gadolinium-enhancing residual tumor on magnetic resonance (MR) T1 imaging, and T2/FLAIR edema with a 2 to 3 cm anatomic expansion. This practice is based on studies showing that nearly 90% of recurrences occur within a 2 cm margin of the primary tumor site.
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Administration of the oral alkylating agent temozolomide during and following radiation was established as the standard of care by the EORTC 22981/26981 and NCIC CE.3 trial. In this trial, 573 GBM patients were randomized to 60 Gy radiation with or without concurrent and adjuvant temozolomide. Temozolomide was given at 75 mg/m 2 daily during radiation and then at 150 to 200 mg/m 2 during the first 5 days of a 4-week cycle for a total of six cycles. The addition of temozolomide improved median survival from 12.1 to 14.6 months and 5-year overall survival from 1.9% to 9.8%.
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The relative benefit from concomitant versus adjuvant temozolomide remains unclear. Notably, intensifying postradiation temozolomide dose in another randomized trial, RTOG 0525, failed to improve survival further. 18 Contemporary randomized trials have utilized postoperative radiation with concurrent and adjuvant temozolomide as a backbone on which to add investigational therapies, and these trials are summarized in ►Table 1.
Other Therapies in the Primary Setting
GBMs are highly vascular tumors, which has led to the study of angiogenesis inhibition as a treatment strategy. Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor A that showed progression-free survival benefit but not overall survival benefit in two phase III randomized trials (►Table 1). In one trial, RTOG 0825, bevacizumab was added to the standard regimen of radiation with concurrent and adjuvant temozolomide. There was no difference in overall survival between the group that received bevacizumab and the group that did not. A progression-free survival benefit was noted in the bevacizumab group (median 10.7 versus 7.3 months), which did not meet the prespecified efficacy target. 19 In the other randomized trial, AVAglio, the addition of bevacizumab to radiation and temozolomide did not confer an advantage in terms Abbreviations: Bev, bevacizumab; GBM, glioblastoma; OS, overall survival; RT, radiation therapy; TMZ, temozolomide; TTF, tumor treating fields. a All tumors in this trial were MGMT methylated.
of overall survival, but there was a statistically significant increase in progression-free survival from 6.2 to 10.6 months. 20 These two trials highlighted several hallmarks of bevacizumab therapy: (1) the agent reduces vascular permeability and alters contrast-enhancement in MR imaging, confounding interpretation of surveillance scans and raising problems with progression-free survival endpoints that may be driven by imaging findings; (2) there is a slight increase in the rate of adverse events, especially thromboembolic and hemorrhagic events, among patients taking bevacizumab. These and other data have relegated bevacizumab to use in carefully selected patients in the newly diagnosed setting. The integrin inhibitor cilengitide is another agent with antiangiogenic activity that failed to improve overall survival when added to standard therapy in the CENTRIC trial (►Table 1). Cilengitide was administered intravenously on a biweekly schedule with both radiation and temozolomide and then administered again after radiation for up to 18 months, with no improvement in survival.
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Two adjuvant therapies have resulted in increased overall survival but have not been routinely adopted in clinical practice. Carmustine wafers (Gliadel) implanted in the resection cavity at the time of surgery to deliver local adjuvant chemotherapy have demonstrated an overall survival benefit in two randomized trials (median 13.9 versus 11.6 months in one trial). 22, 23 However, when non-GBM cases were removed from the analysis in one of these trials, the benefit was no longer statistically significant. 23 Concern regarding adverse effects, including cerebrospinal fluid leakage and intracranial hypertension, and challenges in interpretation of imaging findings after wafer placement have prevented wide adoption of this adjuvant therapy. Tumor-treating fields (TTFs) have also emerged as a novel therapy, with randomized evidence supporting an overall survival benefit. TTFs involve placement of a specialized helmet worn for >18 hours/day that delivers continuous alternating electric fields via transducers placed on the shaved scalp. The EF-14 phase III trial randomized patients to standard radiation with concurrent and adjuvant temozolomide with or without TTF maintenance treatment following radiation completion. The trial was closed early after an overall survival benefit was observed at the first interim analysis and ultimately yielded a benefit of 20.9 versus 16.0 months in the final analysis. 24 The therapy has subsequently gained in popularity, but some authorities have raised concern over the lack of a sham placebo device in the trial, the invasive nature of the device in terms of the patient experience, and the incompletely understood antitumor mechanism.
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Elderly Patients
Nearly half of patients with GBM are diagnosed over the age of 65.
1 Due to upper age limits or poor accrual of such patients in clinical trials, randomized evidence for the elderly population was relatively lacking until recently. To determine whether elderly patients should be treated with the same intensity as younger patients, several studies initially examined whether surgery or radiation provides a survival benefit in the elderly. A Finnish study confirmed that surgical debulking was associated with improved overall survival compared with biopsy alone in patients > 65 years old. 26 Subsequently, a French trial demonstrated that 50 Gy adjuvant radiation improved overall survival relative to supportive care alone in GBM patients > 70 years old with good performance status. 27 Together, these studies support intervention with surgery and radiation rather than supportive care alone in the elderly. With randomized evidence supporting radiation in the elderly, subsequent trials have focused on abbreviating radiation regimens and examining the role of chemotherapy (►Table 2). In one trial, GBM patients ! 60 years old were randomized to conventional 60 Gy in 30 fractions versus hypofractionated 40 Gy in 15 fractions, and no difference in overall survival between the two regimens was observed (44.7% versus 41.7% at 6 months). 28 In a subsequent randomized trial, an extremely hypofractionated regimen of 25 Gy in 5 fractions was explored in a population of elderly (>65) and/or frail (age >50 and KPS 50-70) GBM patients. 29 While this regimen had survival equivalent to that of 40 Gy in 15 fractions, it is likely to have adverse effects on neurocognitive function, which may preclude its adoption. In the German both studied in randomized phase III trials. Given multiple treatment options, therapy selection in recurrent GBM should be individualized, taking into account patient fitness, neurological symptoms, volume of disease, involvement of critical brain structures, and overlap with prior radiation fields. Regardless of therapy choice, overall survival is dismal at $6 to 12 months after recurrence.
Molecular Features Integrated Genomic Analyses
Integrated genomic analyses in the past decade have uncovered mutational, copy number, gene expression, and epigenetic alterations in GBM. [5] [6] [7] [8] The most frequent somatic alterations in GBMs include point mutations in the promoter of the telomerase catalytic subunit TERT (in 60-80% of GBMs), deletion of CDKN2A/B ($50%), amplification or mutation of the receptor tyrosine kinase EGFR ($40%), inactivation of the tumor suppressors TP53 ($30%) and PTEN ($30%), alterations in PIK3CA or PIK3R1 ($20%), CDK4 amplification ($15%), RB1 inactivation ($10%), NF1 mutation ($10%), and IDH1/2 mutation (5-10%).
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Uncommon activating mutations of the kinase BRAF (1-2%) occur in a new 2016 WHO-defined entity called "epithelioid glioblastoma" [44] [45] [46] and are notable given the activity of BRAF-targeted therapies in other cancer types. 47 Most EGFRamplified GBMs contain additional activating mutations or rearrangements of EGFR, such as the EGFR vIII deletion which is present in $30% of GBMs. 8 Pathway analysis has revealed that most GBMs contain alterations in the TP53, RB, and RTK/ PI3K/RAS pathways, and that genes in each pathway tend to be altered in a mutually exclusive manner. For instance, most tumors contain an alteration of at least one RB pathway gene (CDK4, CDK6, CCND2, CDKN2A/B, or RB1). The Cancer Genome Atlas and other groups have proposed classification systems for GBM based on bulk tumor mRNA expression patterns. This has been used to classify tumors as proneural, neural, mesenchymal, or classical subtypes, which associate with specific genetic events and clinical profiles.
7 For example, the proneural subgroup contains the IDH-mutant GBMs; EGFR alterations are enriched in the classical subgroup, and NF1 alterations are enriched in the mesenchymal subgroup. Furthermore, the mesenchymal subtype has been associated with radioresistance, 48 while the proneural subtype was linked to an overall survival benefit from bevacizumab in the AVAglio trial. 49 However, single-cell RNA sequencing has revealed that most GBMs comprise tumor cell subpopulations exhibiting most or all of these expression subtypes, 50 calling into question their clinical utility. DNA methylation signatures have also been proposed to classify GBM, and a glioma CpG island methylator phenotype (G-CIMP) was identified that tightly associates with IDH-mutant GBM. 51 The complexity of these classification schemes and the problem with tumor heterogeneity has limited their translation to the clinic.
MGMT
The DNA repair enzyme MGMT protects against the cytotoxic effect of temozolomide by removing methyl adducts deposited on guanine bases by the drug. Epigenetic silencing of MGMT by methylation of its promoter remains an important GBM prognostic marker and predictor of temozolomide response. In EORTC26981/22981 NCIC CE.3, MGMT promoter methylation was an independent favorable prognostic factor for overall survival. 52 Among patients with MGMT promoter methylation, a survival benefit was observed for those who received temozolomide compared with those who did not (21.7 versus 15.3 months). In the elderly NOA-08 and Nordic trials, temozolomide benefit was similarly observed in patients with MGMT promoter methylation but not in patients without it. In the elderly EORTC 26062/NCIC CE.6 trial, however, a strong trend toward temozolomide benefit was observed in patients whose tumors lacked MGMT promoter methylation. MGMT status may influence the decision to withhold temozolomide or the duration of temozolomide treatment in the elderly (►Fig. 1), although further research is needed given results from the EORTC 26062/NCIC CE.6 trial. Notably, the G-CIMP phenotype partially overlaps with MGMT promoter methylation, which occurs in 79% of G-CIMP tumors yet only 46% of non-G-CIMP tumors. 8 Lastly, in contrast to MGMT promoter methylation which increases temozolomide sensitivity, mutation of mismatch repair (MMR) genes confers temozolomide resistance in cellular models and is associated with GBM recurrence after temozolomide treatment in patients. 69 This mutation is present in not only pediatric tumors but can also occur in GBMs in young adults.
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structures (such as the pons, midbrain, and thalamus) (►Fig. 3), which has led to the definition of "diffuse midline glioma, H3 K27M-mutant" as a new grade IV entity in the 2016 WHO classification. 56 Mechanistically, K27M mutation leads to global reduction in histone H3 K27 trimethylation through impaired recruitment of PRC2 and inhibition of the K27 methylase EZH2 within the PRC2 complex 72,73 (►Fig. 4).
Consistent with this mechanism of pathogenesis, targeted increase in global H3 K27M trimethylation levels using demethylase or deacetylase inhibitors inhibits growth of K27M tumors in xenograft studies. 74, 75 Additional therapeutic targets for K27M tumors include the activin receptor ACVR1, which harbors stimulating mutations in $20% of K27M DIPGs, 76 and the p53 phosphatase PPM1D, which is mutated in nearly 40% of K27M brainstem gliomas in children and adults.
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In addition to K27M, recurrent mutations in Gly34 of histone H3.3 (G34R/V) have been identified in GBMs. While the mutations are just a few amino acids apart in histone H3.3, tumors with G34R/V mutation are clinically and biologically distinct from those with K27M mutation. G34R/V tumors tend to occur in the cerebral hemispheres, follow a more favorable clinical course, and have a different epigenetic signature compared with K27M tumors 71 (►Fig. 3).
Like IDH-mutated GBMs, the G34 GBMs almost invariably contain ATRX mutations. 67 The G34 tumors also appear to comprise a more heterogeneous group, with histopathologic features typical of either GBM or PNETs (primitive neuroectodermal tumors), which has led to the proposal that they be considered a single clinical entity. 46 Proposed mechanisms of oncogenesis for the histone 3 mutations and for other emerging molecular alterations detailed above are shown in ►Fig. 4.
Intratumoral Heterogeneity
Molecular intratumoral heterogeneity occurs commonly in GBMs and can manifest as the presence of different subclones in the same tumor. 78, 85 Ultimately, given the diversity of pathways involved in GBM pathogenesis, combination of molecular therapies will likely be necessary.
Tumor Microtubes as a Novel Mechanism for GBM Progression and Resistance
The recent discovery of ultra-long membranous protrusions that extend from astrocytoma cells, called tumor microtubes (TMs), has changed our understanding of GBM 86,87 (►Fig. 5).
TMs interconnect individual GBM cells in a single communicating syncytium with extensions that invade and colonize the brain by sending nuclear material to distant locations. 
Future Directions
Future advances in GBM treatment will be facilitated by increased understanding of GBM pathogenesis and innovative approaches to exploiting tumor vulnerabilities. Given problems with intratumoral heterogeneity, the most promising targets may be genes whose alterations serve as clonal initiating events. 59 The discovery of hotspot mutations in the TERT promoter and in histone tails raises the question as to whether dependencies in tumors with these alterations can be therapeutically exploited as well. For example, tumors with TERT promoter mutations may develop addictions to pathways regulating transcription factors aberrantly recruited to mutated TERT promoters. Promising therapeutic approaches for histone H3 K27M tumors may involve agents that regulate epigenetic pathways as described above.
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In addition to intratumoral heterogeneity, escape mechanisms are likely responsible for the failure of targeted agents in clinical trials. Such mechanisms allow continued flux through a pathway and can include the activation of downstream effectors by alternative inputs or the loss of pathway inhibitors such as PTEN. 95 An additional reason for the limited efficacy of targeted approaches may be inadequate target suppression as observed for EGFR inhibitors. 95 This finding highlights the importance of assessing pharmacodynamic end points in clinical trials and continued research on strategies to penetrate the blood-brain barrier. Ultimately, difficulties with intratumoral heterogeneity and tumor evolution will likely require combination treatments that target multiple pathways simultaneously and that counter anticipated escape mechanisms. Such combination strategies will benefit from sequential biopsies to assist with therapy selection upon tumor evolution. Immunotherapeutic approaches represent an additional line of promising investigation. GBMs are immunosuppressive due to numerous mechanisms, including decreased MHC expression, increased PD-L1 expression, secretion of antiinflammatory IL-10, and restriction of immune cell infiltration by the blood-brain barrier. 
